Clinical Trial Update: LMN-201 for Prevention of C. Difficile Infection Recurrence [Phase 2, Phase 3]

View source ↗

Summary

LMN-201 is being evaluated to prevent recurrence of Clostridioides difficile infection in Phase 2/Phase 3 trials, and recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• LMN-201

Snippet

Sponsor: Lumen Bioscience, Inc. | Conditions: Clostridioides Difficile Infection | Phase 2, Phase 3 | Status: RECRUITING